Black Diamond Therapeutics (BDTX) Equity Average (2019 - 2021)
Historic Equity Average for Black Diamond Therapeutics (BDTX) over the last 3 years, with Q3 2021 value amounting to $235.0 million.
- Black Diamond Therapeutics' Equity Average fell 2990.47% to $235.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was $235.0 million, marking a year-over-year decrease of 2990.47%. This contributed to the annual value of $130.3 million for FY2020, which is 51563.82% up from last year.
- Per Black Diamond Therapeutics' latest filing, its Equity Average stood at $235.0 million for Q3 2021, which was down 2990.47% from $265.9 million recorded in Q2 2021.
- In the past 5 years, Black Diamond Therapeutics' Equity Average registered a high of $349.2 million during Q2 2020, and its lowest value of -$43.5 million during Q4 2019.
- Its 3-year average for Equity Average is $166.3 million, with a median of $235.0 million in 2021.
- Per our database at Business Quant, Black Diamond Therapeutics' Equity Average skyrocketed by 147877.32% in 2020 and then crashed by 2990.47% in 2021.
- Quarter analysis of 3 years shows Black Diamond Therapeutics' Equity Average stood at -$43.5 million in 2019, then soared by 830.43% to $317.6 million in 2020, then dropped by 26.0% to $235.0 million in 2021.
- Its last three reported values are $235.0 million in Q3 2021, $265.9 million for Q2 2021, and $294.3 million during Q1 2021.